Basal cell carcinoma staging: Difference between revisions
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Basal cell carcinoma}} | {{Basal cell carcinoma}} | ||
{{CMG}} {{AE}} Saarah T. Alkhairy, M.D. | {{CMG}} {{AE}} Saarah T. Alkhairy, M.D.{{M.N}} | ||
==Overview== | ==Overview== | ||
Line 7: | Line 7: | ||
==Basal Cell Carcinoma Staging== | ==Basal Cell Carcinoma Staging== | ||
The [[American Joint Committee on Cancer]] (AJCC) stages basal cell carcinoma based on the [[TNM system]]<ref>{{cite book | last = Amin | first = Mahul | title = AJCC cancer staging manual | publisher = Springer | location = Switzerland | year = 2017 | isbn = 3319406175 }}</ref> | The [[American Joint Committee on Cancer]] (AJCC) stages basal cell carcinoma based on the [[TNM system]]:<ref>{{cite book | last = Amin | first = Mahul | title = AJCC cancer staging manual | publisher = Springer | location = Switzerland | year = 2017 | isbn = 3319406175 }}</ref><br>T - [[tumor]]<br>N - [[lymph nodes]]<br>M - [[metastasis]] | ||
The following table summarizes the '''T''' [[categories]]: | The following table summarizes the '''T''' [[categories]]: | ||
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | {| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | ||
| align="center" style="background:# | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''T Categories'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Description'''}} | |||
|- | |- | ||
Line 50: | Line 50: | ||
The following table summarizes the '''N''' categories: | The following table summarizes the '''N''' categories: | ||
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | {| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | ||
| align="center" style="background:# | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''N categories'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Description'''}} | |||
|- | |- | ||
Line 96: | Line 96: | ||
The following table summarizes the '''M''' categories: | The following table summarizes the '''M''' categories: | ||
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | {| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | ||
| align="center" style="background:# | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''M categories'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Description'''}} | |||
|- | |- | ||
Line 112: | Line 112: | ||
The T, N, and M categories are combined into stages. The following table summarizes the '''stage grouping'''. | The T, N, and M categories are combined into stages. The following table summarizes the '''stage grouping'''. | ||
{| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | {| {{table}} cellpadding="4" cellspacing="0" style="border:#c9c9c9 1px solid; margin: 1em 1em 1em 0; border-collapse: collapse;" | ||
| align="center" style="background:# | | align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''Stage'''}} | ||
| align="center" style="background: #4479BA;" | {{fontcolor|#FFF|'''TNM Grouping'''}} | |||
|- | |- | ||
Line 141: | Line 141: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] |
Latest revision as of 18:22, 4 April 2019
Basal cell carcinoma Microchapters |
Diagnosis |
---|
Case Studies |
Basal cell carcinoma staging On the Web |
American Roentgen Ray Society Images of Basal cell carcinoma staging |
Risk calculators and risk factors for Basal cell carcinoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Saarah T. Alkhairy, M.D. Maneesha Nandimandalam, M.B.B.S.[2]
Overview
The American Joint Committee on Cancer (AJCC) stages basal cell carcinoma based on the TNM system. T, M, and N are combined into stages, called stage grouping.
Basal Cell Carcinoma Staging
The American Joint Committee on Cancer (AJCC) stages basal cell carcinoma based on the TNM system:[1]
T - tumor
N - lymph nodes
M - metastasis
The following table summarizes the T categories:
T Categories | Description |
TX | Primary tumor cannot be identified |
Tis | Carcinoma in situ |
T1 | Tumor ≤2 cm in greatest dimension |
T2 | Tumor >2 cm, but ≤4 cm in greatest dimension |
T3 | Tumor >4 cm in maximum dimension or minor bone erosion or perineural invasion or deep invasion |
T4 | Tumor with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion |
T4a | Tumor with gross cortical bone/marrow invasion |
T4b | Tumor with skull base invasion and/or skull base foramen involvement |
The following table summarizes the N categories:
N categories | Description |
NX | Regional lymph nodes cannot be assessed |
N0 | No regional lymph node metastasis |
N1 | Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension and ENE negative |
N2 | Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension and ENE positive; or >3 cm but ≤6 cm in greatest dimension and ENE negative; or metastases in multiple ipsilateral lymph nodes, none >6 cm in greatest dimension and ENE negative; or in bilateral or contralateral lymph node(s), none >6 cm in greatest dimension, ENE negative. |
N2a | Metastasis in single ipsilateral node ≤3 cm in greatest dimension and ENE positive; or a single ipsilateral node >3 cm but ≤6 cm in greatest dimension and ENE negative. |
N2b | Metastasis in multiple ipsilateral nodes, none >6 cm in greatest dimension and ENE negative. |
N2c | Metastasis in bilateral or contralateral lymph node(s), none >6 cm in greatest dimension and ENE negative. |
N3 | Metastasis in a lymph node >6 cm in greatest dimension and ENE negative; or in a single ipsilateral node >3 cm in greatest dimension and ENE positive; or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE-positive status; or a single contralateral node of any size and ENE positive. |
N3a | Metastasis in a lymph node >6 cm in greatest dimension and ENE negative. |
N3b | Metastasis in a single ipsilateral node >3 cm in greatest dimension and ENE positive; or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE-positive status; or a single contralateral node of any size and ENE positive. |
The following table summarizes the M categories:
M categories | Description |
M0 | No distant metastasis |
M1 | Distant metastasis |
The T, N, and M categories are combined into stages. The following table summarizes the stage grouping.
Stage | TNM Grouping |
0 | Tis, N0, M0 |
I | T1, N0, M0 |
II | T2, N0, M0 |
III | T3, N0, M0; T1-T3, N1, M0 |
IV | T1-T3, N2, M0; Any T, N3, M0; T4, any N, M0; Any T, any N, M1 |
References
- ↑ Amin, Mahul (2017). AJCC cancer staging manual. Switzerland: Springer. ISBN 3319406175.